MedTrace Logo

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

NCT06116240 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2023-11-03

No results posted yet for this study

Summary

This is a Phase Ib clinical trial to evaluate the safety and efficacy of TQB2450 injection combined with AL2846 capsules in patients with advanced solid tumors.

Conditions

Interventions

DRUG

TQB2450 injection

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

DRUG

AL2846 capsule

AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

DRUG

Pemetrexed disodium for injection

Pemetrexed disodium is a multi-target antifolate antineoplastic drug.

DRUG

Cisplatin injection

Cisplatin is a chemotherapy drug.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-02
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06116240 on ClinicalTrials.gov